What is the current gut microbiome market size?

The gut microbiome market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the gut microbiome market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the gut microbiome market?

Key drivers include rising awareness of gut health and its impact on overall wellness, and advancements in research.

What are the major challenges facing the gut microbiome market?

Challenges include regulatory frameworks, high research costs, and varying regional standards.

Which regions are leading the gut microbiome market?

North America and Europe are currently leading the market due to high investment in research.

Who are the top companies in the gut microbiome market?

Top companies include Pfizer, Johnson & Johnson, and Nestle, among others, driving innovation.

What are the future opportunities in the gut microbiome market?

Future opportunities include personalized nutrition, and therapeutic applications, offering a promising future outlook.

How is technology impacting the gut microbiome market?

Technology is advancing research, diagnostics, and treatment options, improving the gut microbiome market size and growth.

What is the current regulatory landscape for the gut microbiome market?

The regulatory landscape is evolving, with increasing focus on safety, efficacy, and standardization of products.

How will the gut microbiome market evolve in the next 5 years?

The market will experience significant growth, driven by increasing demand, and advancements in technology and research.

gut microbiome Growth, Trends & Forecast Outlook 2033

gut microbiome by Application (Human, Animal), by Types (Obesity, Inflammatory Bowel Disease (IBD), Diabetes, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $15.5 million

CAGR: 22.1%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $15.5 million

CAGR: 22.1%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

gut microbiome Market Overview

The gut microbiome market refers to the industry focused on the ecosystem of microorganisms living in the human gut, with relevance to overall health and wellness. As the gut microbiome market size is estimated to be around $1.4 billion, the growth outlook for this industry is promising, with a market forecast indicating significant expansion over the next few years. The industry expansion is driven by factors such as increasing awareness of the importance of gut health, advancements in technology, and growing demand for probiotics and prebiotics. The scope of this market encompasses various segments, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, with applications in food and beverages, pharmaceuticals, and animal health.

Loading chart…

The current gut microbiome market size is driven by a growth forecast of around 20% CAGR, with macro drivers such as increasing awareness of gut health, advancements in technology, and growing demand for probiotics and prebiotics. Key forces shaping the industry include technology shifts, such as the development of next-generation probiotics, regulations, such as those related to food safety and labeling, and consumer behavior, with growing demand for health and wellness products. The largest region for the gut microbiome market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing awareness and demand for probiotics and prebiotics in countries such as China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	15.50 million
Revenue forecast in 2033	76.57 million
Growth rate	CAGR of 22.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Viome; Carbiotix; Ixcela, Inc.; Novome Biotechnologies; Kintai Therapeutics; ProDigest; Caelus Health; LNC Therapeutics; AnimalBiome; Assembly Biosciences; Enterome BioScience
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The gut microbiome market is poised for significant growth, driven by increasing awareness of the importance of gut health and its impact on overall well-being. The gut microbiome market size is expected to expand rapidly, with a growth forecast that underscores the potential for innovation and investment in this space.

Growth Drivers2 items

Advances in technological capabilities, such as next-generation sequencing and metagenomics, are enabling a deeper understanding of the gut microbiome and its role in human health, driving growth in the gut microbiome market

Increasing demand for personalized nutrition and health products is fueling the development of gut microbiome-based solutions, contributing to the growth forecast of the market

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players into the gut microbiome market, potentially constraining its growth forecast

The complexity of the gut microbiome and the need for standardized testing and validation protocols are creating challenges for companies seeking to develop and market effective gut microbiome-based products

Opportunities2 items

The growing awareness of the link between the gut microbiome and chronic diseases is creating opportunities for companies to develop innovative products and services that address these conditions, driving growth in the gut microbiome market size

Partnerships and collaborations between companies, research institutions, and healthcare organizations are facilitating the development of new gut microbiome-based therapies and products, supporting the growth forecast of the market

Challenges2 items

The lack of standardization in gut microbiome testing and analysis is hindering the development of effective products and therapies, and creating challenges for companies operating in the gut microbiome market

The need for long-term clinical trials and outcome studies to demonstrate the efficacy and safety of gut microbiome-based products is a significant challenge for companies seeking to commercialize these products and achieve a strong growth forecast

Market Segmentation

Loading chart…

The gut microbiome market can be segmented based on application, which includes diseases such as inflammatory bowel disease, obesity, and mental health disorders. This segmentation contributes to the overall gut microbiome market size by highlighting the various areas where gut microbiome-based products and therapies can be applied, thus driving growth and innovation in the market. Understanding the gut microbiome segmentation is crucial for industry players to identify potential opportunities and develop targeted solutions.

Another way to segment the gut microbiome market is by types, which includes probiotics, prebiotics, synbiotics, and fecal microbiota transplantation. Each of these subtypes has its own unique characteristics and applications, contributing to the overall market size. For instance, probiotics are widely used in food and beverages, while fecal microbiota transplantation is a promising area of research for treating various diseases. Analyzing the market taxonomy of these subtypes is essential for companies to develop effective strategies and stay competitive in the market.

gut microbiome Segmentation Breakdown8 items

Application

Human

Animal

Types

Obesity

Inflammatory Bowel Disease (IBD)

Diabetes

Others

Regional Insights

Loading chart…

The gut microbiome market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of gut microbiome-based products and services. Key drivers for North America include significant investments in research and development, favorable policies, and a mature ecosystem.

In Europe, key drivers include a high level of awareness about gut health, a strong infrastructure for research and development, and a growing demand for microbiome-based products. Asia Pacific is driven by a large and growing demographics, increasing investment in healthcare infrastructure, and a rising awareness of gut health. Latin America and Middle East & Africa are expected to experience growth due to improving infrastructure, increasing adoption of gut microbiome-based products, and favorable policies.

The regional forecast indicates that the gut microbiome market will continue to grow, with each region contributing to the overall gut microbiome market growth. Understanding the key drivers and trends in each region is crucial for businesses and organizations looking to capitalize on the growing demand for gut microbiome-based products and services.

Competitive Landscape

The gut microbiome market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, and regulatory approvals. The gut microbiome competitive landscape is characterized by high competition, with companies seeking to differentiate themselves through various strategies. Key competitive levers include pricing, with companies offering premium products and services, and distribution, with a focus on expanding reach and accessibility.

Companies in the gut microbiome market employ various strategies to differentiate themselves and stay competitive. These strategies include M&A, partnerships, product launches, expansion, R&D, and localization. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To overcome these challenges, companies focus on developing unique technologies, service models, and channel strengths to differentiate themselves and maintain a competitive edge. The following companies have adopted distinct strategies:

Viome: regional expansion

Carbiotix: innovation pipeline

Ixcela, Inc.: premium pricing

Novome Biotechnologies: vertical integration

Kintai Therapeutics: local manufacturing

ProDigest: OEM tie-ups

Key gut microbiome Companies11 items

Viome

Carbiotix

Ixcela, Inc.

Novome Biotechnologies

Kintai Therapeutics

ProDigest

Caelus Health

LNC Therapeutics

AnimalBiome

Assembly Biosciences

Enterome BioScience

Market Ecosystem

The gut microbiome market operates within a complex ecosystem, spanning upstream, midstream, and downstream segments. This ecosystem encompasses technology providers and suppliers, integrators, channels, and end users, all of which contribute to the creation and capture of value. Understanding the gut microbiome ecosystem is crucial for navigating the value chain analysis and identifying key areas of opportunity and challenge.

Raw material/component suppliers — provide microbiome sampling kits

Technology providers — develop microbiome analysis software

OEMs / manufacturers — produce gut microbiome testing equipment

System integrators / EPCs — integrate microbiome data into healthcare systems

Distributors / channel partners — supply gut microbiome products to healthcare providers

Regulators/standards bodies — establish guidelines for gut microbiome testing and research

Data/analytics providers — offer insights and analysis of gut microbiome data

Within the gut microbiome ecosystem, control points are largely influenced by regulators and standards bodies, as they dictate the approval and adoption of new technologies and products. Dependency risks arise from input constraints, such as the availability of high-quality microbiome samples, and standards, including those related to data privacy and security. Switching costs and partnerships are also critical, as companies must balance the need for interoperability with the risks of data sharing and collaboration. The gut microbiome ecosystem differs by region, with varying levels of investment in research and development, as well as distinct regulatory frameworks, shaping the landscape of this complex and evolving market.

Recent Industry Insights

The gut microbiome industry trends have witnessed significant developments over the last 12-18 months, driven by advancements in research and technology. Recent partnerships, such as collaborations between biotechnology firms and research institutions, have accelerated innovation in the field. Notable mergers and acquisitions have also taken place, enabling companies to expand their product portfolios and enhance their market presence.

Furthermore, several product launches have occurred, introducing novel therapeutics and diagnostics that target the gut microbiome. Regulatory changes, such as updated guidelines for clinical trials, have also impacted the industry. A shift in consumer trends towards personalized health and wellness has fueled demand for gut microbiome-related products and services. Additionally, funding rounds and expansions have provided companies with the necessary resources to drive research and development, shaping the future of the gut microbiome industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the gut microbiome market. The market attractiveness is high due to increasing awareness of the link between gut health and overall well-being. Competitive intensity is moderate, with key players investing in research and development to stay ahead. The long-term outlook for the gut microbiome market outlook is positive, driven by growing demand for probiotics and prebiotics. Innovation in the landscape is rapid, with new product launches and partnerships emerging regularly. However, the demand–supply balance is fragile, with supply chain disruptions and regulatory challenges posing risks. Key risk factors include regulatory uncertainty and supply chain volatility.

11 items

1. Executive Summary

2. gut microbiome Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global gut microbiome Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global gut microbiome Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Human

6.1.2. Animal

6.2. Global gut microbiome Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Obesity

6.2.2. Inflammatory Bowel Disease (IBD)

6.2.3. Diabetes

6.2.4. Others

6.3. Global gut microbiome Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global gut microbiome Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global gut microbiome Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global gut microbiome Market Competition by Key Manufacturers

8.1. Global gut microbiome Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global gut microbiome: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Viome

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Carbiotix

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ixcela, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novome Biotechnologies

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Kintai Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. ProDigest

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Caelus Health

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. LNC Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. AnimalBiome

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Assembly Biosciences

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Enterome BioScience

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global gut microbiome Market

Figure 4: Global gut microbiome Market: Drivers

Figure 5: Global gut microbiome Market: Challenges

Figure 6: Global gut microbiome Market: Trends

Figure 7: Global gut microbiome Market: Opportunity

Figure 8: Global gut microbiome Market: Restraint

Figure 9: Global gut microbiome Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global gut microbiome Market Value (USD Million) By Region

Figure 15: Global gut microbiome Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global gut microbiome Market Value (USD Million) By Region

Figure 23: Global gut microbiome Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global gut microbiome Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global gut microbiome Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global gut microbiome Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global gut microbiome Market Value (USD Million) By Region

Table 10: Global gut microbiome Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global gut microbiome Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global gut microbiome Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global gut microbiome Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Viome Basic Information And Sales Area

Table 31: Viome. Products Portfolio

Table 32: Carbiotix Basic Information And Sales Area

Table 33: Carbiotix. Products Portfolio

Table 34: Ixcela, Inc. Basic Information And Sales Area

Table 35: Ixcela, Inc.. Products Portfolio

Table 36: Novome Biotechnologies Basic Information And Sales Area

Table 37: Novome Biotechnologies. Products Portfolio

Table 38: Kintai Therapeutics Basic Information And Sales Area

Table 39: Kintai Therapeutics. Products Portfolio

Table 40: ProDigest Basic Information And Sales Area

Table 41: ProDigest. Products Portfolio

Table 42: Caelus Health Basic Information And Sales Area

Table 43: Caelus Health. Products Portfolio

Table 44: LNC Therapeutics Basic Information And Sales Area

Table 45: LNC Therapeutics. Products Portfolio

Table 46: AnimalBiome Basic Information And Sales Area

Table 47: AnimalBiome. Products Portfolio

Table 48: Assembly Biosciences Basic Information And Sales Area

Table 49: Assembly Biosciences. Products Portfolio

Table 50: Enterome BioScience Basic Information And Sales Area

Table 51: Enterome BioScience. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global gut microbiome Market Value (USD Million) By Region

Table 57: Global gut microbiome Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

gut microbiome Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	15.50 million
Revenue forecast in 2033	76.57 million
Growth rate	CAGR of 22.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Viome; Carbiotix; Ixcela, Inc.; Novome Biotechnologies; Kintai Therapeutics; ProDigest; Caelus Health; LNC Therapeutics; AnimalBiome; Assembly Biosciences; Enterome BioScience
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing demand for personalized nutrition and health products is fueling the development of gut microbiome-based solutions, contributing to the growth forecast of the market

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players into the gut microbiome market, potentially constraining its growth forecast

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

gut microbiome Segmentation Breakdown8 items

Application

Human

Animal

Types

Obesity

Inflammatory Bowel Disease (IBD)

Diabetes

Others

Regional Insights

Loading chart…

Competitive Landscape

Viome: regional expansion

Carbiotix: innovation pipeline

Ixcela, Inc.: premium pricing

Novome Biotechnologies: vertical integration

Kintai Therapeutics: local manufacturing

ProDigest: OEM tie-ups

Key gut microbiome Companies11 items

Viome

Carbiotix

Ixcela, Inc.

Novome Biotechnologies

Kintai Therapeutics

ProDigest

Caelus Health

LNC Therapeutics

AnimalBiome

Assembly Biosciences

Enterome BioScience

Market Ecosystem

Raw material/component suppliers — provide microbiome sampling kits

Technology providers — develop microbiome analysis software

OEMs / manufacturers — produce gut microbiome testing equipment

System integrators / EPCs — integrate microbiome data into healthcare systems

Distributors / channel partners — supply gut microbiome products to healthcare providers

Regulators/standards bodies — establish guidelines for gut microbiome testing and research

Data/analytics providers — offer insights and analysis of gut microbiome data

Recent Industry Insights

Analyst Overview

Table of Contents